About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
MOXIFLOXACIN exhibits a multivector biochemical action pattern, influencing enzymatic cascades, receptormediated signalling, intracellular ion behaviour, mitochondrial oxidative dynamics and transcriptional regulatory networks. Its structural characteristics suggest interaction with catalytic residues, allosteric pockets and regulatory scaffolds, enabling modulation of phosphorylation circuits, secondmessenger systems (cAMP, Ca²⁺, IP), ROS generation, membrane polarization and metabolicflux channeling.
Depending on biological context, MOXIFLOXACIN may alter mitochondrial membrane potential, redox buffering capacity, calcium sequestration, cytoskeletal integrity, vesicle trafficking efficiency and transcriptionfactor activation, resulting in broad mechanistic adaptability across experimental systems.
Benefits and Advantages
This compound is highly valued in advanced biochemical and pharmacological research frameworks, including:
- Highresolution receptorligand mapping and affinity prediction
- Enzymekinetic profiling and catalyticpathway deconstruction
- Mitochondrialstress testing, ATPflux analysis and ROSequilibrium studies
- Integrated multiomics research: transcriptomics, metabolomics, proteomics, phosphoproteomics
- Cytoskeletal modelling involving actin/tubulin regulation
- Apoptosis, autophagy, necroptosis and ferroptosis signalling investigations
- Structureactivity relationship (SAR) exploration and molecular optimisation
- Pharmacodynamic simulations for mechanistic threshold and doseresponse studies
Side Effects and Risks
Possible laboratoryobserved risks include:
- Redox imbalance with elevated ROS levels
- Mitochondrial overactivation or respiratorychain suppression
- Ionchannel dysregulation affecting Na⁺/K⁺/Ca²⁺ flow
- Crossactivation or inhibition of unintended receptor systems
- Cytoskeletal destabilisation and impaired membrane integrity
- Dosedependent cytotoxicity or induction of apoptotic/autophagic pathways
- Transcriptional instability and activation of inflammatory cascades (NF-κB, JNK, p38)
Strict biosafety handling, controlled dosing and regulated environmental conditions are required for all experimental use. Not intended for human or veterinary application.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C21H24FN3O4 |
|---|---|
| Molecular Weight | 401.4 g/mol |
| CAS Number | 151096-09-2 |
| Storage Condition | Store at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F) |
| Solubility | 1.68e-01 g/L |
| Purity | Purity information is available upon request (COA). |
| Synonym | moxifloxacin; 151096-09-2; Moxifloxacine; Zimoxin; Avelox IV |
| IUPAC/Chemical Name | 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid |
| InChl Key | FABPRXSRWADJSP-MEDUHNTESA-N |
| InChl Code | InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
